Please login to the form below

Not currently logged in
Email:
Password:

erlotinib

This page shows the latest erlotinib news and features for those working in and with pharma, biotech and healthcare.

FDA approval gained, Pfizer sets sights on first-line NSCLC market

FDA approval gained, Pfizer sets sights on first-line NSCLC market

The second-generation EGFR tyrosine kinase inhibitor has been shown in trials to be more effective that first-generation drugs such as AstraZeneca’s Iressa (gefitinib) and Roche’s Tarceva (erlotinib)

Latest news

More from news
Approximately 4 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • Market access opportunities in China Market access opportunities in China

    For example, although Roche's Tarceva (erlotinib hydrochloride) has not been included in any reimbursement lists in China, it has paved the way by collaborating with the China Charity Federation to

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Novocure’s chief commercial officer to step down Novocure’s chief commercial officer to step down

    Previously, he was senior vice president for sales and marketing at OSI Pharmaceuticals, where he led the global commercialisation of Tarceva (erlotinib) from 2003 to 2011.

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib).

  • Astellas poaches new oncology head from Takeda Astellas poaches new oncology head from Takeda

    She will now lead Astellas' efforts in cancer, which include prostate cancer drug Xtandi (enzalutamide) and Tarveca (erlotinib) – a lung cancer drug co-marketed by Roche.

  • Cipla appoints Novartis’ Subhanu Saxena as CEO Cipla appoints Novartis’ Subhanu Saxena as CEO

    Cipla has also been busy challenging big pharma patents, and in September won a four-year battle to market its own version of Roche's cancer drug  Tarceva  (erlotinib).

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Ashfield

Ashfield, part of UDG Healthcare plc, is a global leader in commercialisation services for the healthcare industry. We partner with...

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics